close

Agreements

Date: 2017-11-29

Type of information: Establishment of a new subsidiary in the EU

Compound: Solutions Center on the Genopole Campus in Évry

Company: Illumina (USA - CA)

Therapeutic area: Technology - Services

Type agreement: establishment of a new subsidiary in the EU

Action mechanism:

Disease:

Details:

  • • On November 29, 2017, Illumina announced the opening of its Solutions Center on the Genopole Campus in Évry, near Paris . The leading-edge customer training center will offer demonstrations, instruction, and education in the latest genomics technologies from Illumina for up to 1,000 scientists a year, providing direct links to Illumina's global network of facilities and in-house experts.
  • The center will also accommodate Illumina's first commercial office on the European continent to provide support in the development of skills for the expanding genomics industry in France . " Illumina's unmatched success and reputation as a global leader in genomics is the perfect fit for the Genopole campus, which brings together the key elements needed for our business to thrive, and we look forward to extending our relationships in France ," said Paula Dowdy , Senior Vice President and General Manager, Illumina , Europe , Middle East , and Africa . "The French government's commitment to its own Genome Project demonstrates the value it places on genomics as part of the strategy to provide better future healthcare." Genopole, France's leading biocluster for biotechnologies and research in genomics and genetics, is built upon the model of American and European campuses and unites innovative high-tech life sciences companies, public and private research and higher education facilities at a single site in Évry, near Paris . "France Médecine Génomique 2025 - the national personalized medicine initiative - has also selected Genopole for its Reference, Expertise, Innovation and Transfer Center (CREFIX), thus building on the strength of the National Research Center on Human Genomics already established on our site by the French Alternative Energies and Atomic Energy Commission (CEA) said Jean-Marc Grognet , CEO of Genopole. The arrival of Illumina demonstrates the central role that Genopole plays in the development of personalized medicine and we are happy that its Solutions Center will attract more users to our site."

Financial terms:

Latest news:

Is general: Yes